Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.055 AUD
−5.48 M AUD
0.00 AUD
114.98 M
About ARGENICA THERAPEUTICS LIMITED
Sector
Industry
CEO
Liz Dallimore
Website
Headquarters
Nedlands
Founded
2019
ISIN
AU0000150328
FIGI
BBG010YS0TD1
Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AGN is 0.645 AUD — it has increased by 5.74% in the past 24 hours. Watch ARGENICA THERAPEUTICS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange ARGENICA THERAPEUTICS LIMITED stocks are traded under the ticker AGN.
AGN stock has fallen by −1.53% compared to the previous week, the month change is a −11.64% fall, over the last year ARGENICA THERAPEUTICS LIMITED has showed a 26.47% increase.
We've gathered analysts' opinions on ARGENICA THERAPEUTICS LIMITED future price: according to them, AGN price has a max estimate of 1.40 AUD and a min estimate of 1.40 AUD. Watch AGN chart and read a more detailed ARGENICA THERAPEUTICS LIMITED stock forecast: see what analysts think of ARGENICA THERAPEUTICS LIMITED and suggest that you do with its stocks.
AGN stock is 5.56% volatile and has beta coefficient of 1.15. Track ARGENICA THERAPEUTICS LIMITED stock price on the chart and check out the list of the most volatile stocks — is ARGENICA THERAPEUTICS LIMITED there?
Yes, you can track ARGENICA THERAPEUTICS LIMITED financials in yearly and quarterly reports right on TradingView.
ARGENICA THERAPEUTICS LIMITED is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
AGN net income for the last half-year is −4.07 M AUD, while the previous report showed −1.41 M AUD of net income which accounts for −188.74% change. Track more ARGENICA THERAPEUTICS LIMITED financial stats to get the full picture.
No, AGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARGENICA THERAPEUTICS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ARGENICA THERAPEUTICS LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ARGENICA THERAPEUTICS LIMITED stock shows the neutral signal. See more of ARGENICA THERAPEUTICS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.